Elementis (ELM): Pharma proceeds share buyback

This situation live

£1,023m · 181.2p · +4% since the first step

Capital return

Pharma proceeds share buyback

New c£25m buyback launched

Next: buyback execution using pharma sale proceeds

Every step · 1

30 Jul 2026 New c£25m buyback launched – New share buyback programme of c£25m (c$35m) launched using net cash proceeds from the sale of the pharmaceutical manufacturing business. ↗

What is happening

Elementis: Pharma proceeds share buyback – New c£25m buyback launched. ['New c£25m buyback launched']

In short: The sale of the pharma business to ABF was agreed on 5 March 2026 with net cash proceeds to be returned to shareholders, and completed on 2 June 2026. The H1 results of 30 July 2026 confirm a new c£25m (c$35m) buyback has been launched, with net debt at $163.8m (1.1x EBITDA).
Announced: 30 Jul 2026 · New c£25m buyback launched
Size: c£25m (c$35m)
Funding: Net cash proceeds from sale of the pharmaceutical manufacturing business
Status: Launched, announced with H1 results on 30 July 2026
Net debt: $163.8m at 30 June 2026, 1.1x EBITDA

buyback execution using pharma sale proceeds.

From the company's own announcements. Not investment advice.

Briefing Pro

What it does, how it got here, what management promised and delivered – written from its own announcements.

Also at Elementis 1 open